Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M708596200 on October 19, 2007

J. Biol. Chem., Vol. 282, Issue 50, 36454-36462, December 14, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/50/36454    most recent
M708596200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moffatt, P.
Right arrow Articles by Lanctôt, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moffatt, P.
Right arrow Articles by Lanctôt, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Osteocrin Is a Specific Ligand of the Natriuretic Peptide Clearance Receptor That Modulates Bone Growth*Formula

Pierre Moffatt{ddagger}**12, Gethin Thomas§1, Karine Sellin||, Marie-Claude Bessette||, François Lafrenière||, Omar Akhouayri{ddagger}, René St-Arnaud{ddagger}**, and Christian Lanctôt||

From the {ddagger}Shriners Hospital for Children, Montréal, Québec H3G 1A6, Canada, **Department of Human Genetics, McGill University, Montréal, Québec H3A 2T5, Canada, §Enobia Pharma, Montréal, Québec H1W 4A4, Canada, Diamantina Institute for Cancer, Immunology, and Metabolic Medicine, The University of Queensland, Princess Alexandria Hospital, Brisbane, Australia, and ||Phenogene Therapeutics, Montréal, Québec H3A 1L2, Canada

Osteocrin (Ostn) is a recently discovered secreted protein produced by cells of the osteoblast lineage that shows a well conserved homology with members of the natriuretic peptide (NP) family. We hypothesized that Ostn could interact with the NP receptors, thereby modulating NP actions on the skeleton. Ostn binds specifically and saturably to the NP peptide receptor-C (NPR-C) receptor with a Kd of ~5 nM with no binding to the GC-A or GC-B receptors. Deletion of several of the residues deemed important for NP binding to NPR-C led to abolition of Ostn binding, confirming the presence of a "natriuretic motif." Functionally, Ostn was able to augment C-type natriuretic peptide-stimulated cGMP production in both pre-chondrocytic (ATDC5) and osteoblastic (UMR106) cells, suggesting increased NP levels due to attenuation of NPR-C associated NP clearance. Ostn-transgenic mice displayed elongated bones and a marked kyphosis associated with elevated bone cGMP levels, suggesting that elevated natriuretic peptide activity contributed to the increased bone length possibly through an increase in growth plate chondrocyte proliferation. Thus, we have demonstrated that Ostn is a naturally occurring ligand of the NPR-C clearance receptor and may act to locally modulate the actions of the natriuretic system in bone by blocking the clearance action of NPR-C, thus locally elevating levels of C-type natriuretic peptide.


Received for publication, October 16, 2007

* This work was supported in part by the Shriners of North America. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1-3.

1 These authors contributed equally to this work.

2 To whom correspondence should be addressed: Shriners Hospital for Children, 1529 Cedar Ave., Montréal, Québec H3G 1A6, Canada. Tel.: 514-282-7161; Fax: 514-842-5581; E-mail: pmoffatt{at}shriners.mcgill.ca.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J EndocrinolHome page
S. Kita, H. Nishizawa, Y. Okuno, M. Tanaka, A. Yasui, M. Matsuda, Y. Yamada, and I. Shimomura
Competitive binding of musclin to natriuretic peptide receptor 3 with atrial natriuretic peptide
J. Endocrinol., May 1, 2009; 201(2): 287 - 295.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
T. C R Prickett, G. K Barrell, M. Wellby, T. G Yandle, A M. Richards, and E. A Espiner
Effect of sex steroids on plasma C-type natriuretic peptide forms: stimulation by oestradiol in lambs and adult sheep
J. Endocrinol., December 1, 2008; 199(3): 481 - 487.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement